Notice To Announce Request for Information (RFI) Inviting Input on the ICCFASD 2022-2026 Strategic Plan Outline, 36567-36568 [2021-14689]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person. Any
member of the public may submit written
comments no later than 15 days after the
meeting.
Information is also available on the
Institute’s/Center’s home page: https://
www.nccih.nih.gov/news/events/advisorycouncil-78th-meeting, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: July 7, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–14739 Filed 7–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: High ASS1 Expressing
Tumors Embody a Purine Rich
Genomic Signature and Sensitivity to
Purine Depletion
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute
(NCI), an institute of the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive,
sublicensable patent license to Yeda
Research & Development Co, Ltd
(‘‘YEDA’’), the technology transfer
company of the Weizmann Institute of
Science, a non-profit research
institution located in Rehovot, Israel for
NCI’s rights to the patent applications
listed in the Supplementary Information
section of this notice.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before July 27, 2021 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Kevin W. Chang, Ph.D.,
Senior Licensing and Patenting Manager
at Telephone: (240)–276–6910 or at
Email: changke@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:26 Jul 09, 2021
Jkt 253001
Intellectual Property
The following and all continuing U.S.
and foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to YEDA: PCT Patent
Application PCT/IL2020/050708, filed
June 24, 2020 and entitled ‘‘High ASS1
Expressing Tumors Embody A Purine
Rich Genomic Signature And Sensitivity
To Purine Depletion’’ [HHS Reference
No. E–210–2020–0–PCT–01].
The patent rights in these inventions
have been assigned to the Government
of the United States of America and
YEDA. The prospective license will be
for the purpose of consolidating the
patent rights to YEDA, one of the coowners of said rights, for commercial
development and marketing.
Consolidation of these co-owned rights
is intended to expedite development of
the invention, consistent with the goals
of the Bayh-Dole Act codified as 35
U.S.C. 200–212.
The prospective patent license will be
worldwide, exclusive, and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by YEDA will be
subject to the provisions of 37 CFR parts
401 and 404.
This technology discloses methods of
treating a high argininosuccinate
synthase (ASS1) expressing solid tumor
with a combination of a purine synthase
inhibitor or an agent that increases the
pyrimidine to purine ratio in a cell, and
an immune-modulating drug, such as a
checkpoint inhibitor.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
include terms for the sharing of royalty
income with NCI from commercial
sublicenses of the patent rights. The
prospective exclusive license may be
granted unless within fifteen (15) days
from the date of this published notice,
the National Cancer Institute receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license
that are timely filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
patent license. In response to this
Notice, the public may file comments or
objections. Comments and objections,
other than those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
36567
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: July 6, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2021–14681 Filed 7–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice To Announce Request for
Information (RFI) Inviting Input on the
ICCFASD 2022–2026 Strategic Plan
Outline
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Interagency Coordinating
Committee on Fetal Alcohol Spectrum
Disorders (ICCFASD) is developing an
updated strategic plan to guide its
efforts over the next five years. As
sponsor and chair of the ICCFASD, the
National Institute on Alcohol Abuse and
Alcoholism (NIAAA) will be issuing a
Request for Information to seek
comments on the draft outline of the
ICCFASD’s 2022–2026 Strategic Plan
from diverse stakeholders, including
scientific experts, health care providers,
patients and family members, advocacy
groups, other federal agencies, and nongovernmental scientific, professional,
and healthcare organizations.
DATES: Comments must be received by
August 31, 2021, to ensure
consideration. Responses will be
reviewed by ICCFASD members and
considered during the development of
the 2022–2026 Strategic Plan.
ADDRESSES: To view and comment on
the strategic plan outline, please visit
our online response form: RFI online
response form.
FOR FURTHER INFORMATION CONTACT:
Tatiana Balachova, ICCFASD Executive
Secretary, National Institute on Alcohol
Abuse and Alcoholism, NIH, 6700B
Rockledge Drive, Bethesda, MD 20817.
Phone: 301–443–5726, Email: NIAAAICCFASD@mail.nih.gov.
SUPPLEMENTARY INFORMATION: In
accordance with the 21st Century Cures
Act, NIH institutes are required to
SUMMARY:
E:\FR\FM\12JYN1.SGM
12JYN1
36568
Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices
regularly update their strategic plans.
The Interagency Coordinating
Committee on Fetal Alcohol Spectrum
Disorders (ICCFASD) fosters improved
communication, cooperation, and
collaboration among disciplines and
federal agencies that address health,
education, developmental disabilities,
alcohol research, and social services and
justice issues related to prenatal alcohol
exposure. The ICCFASD envisions that
collaborative partnerships, using the
resources of the federal government in
partnership with other organizations,
will lead to improved prevention of
prenatal alcohol exposure, earlier
identification and improved
surveillance of fetal alcohol spectrum
disorders (FASD), and more effective
interventions and services for
individuals living with FASD as well as
their families. ICCFASD is sponsored
and chaired by the National Institute on
Alcohol Abuse and Alcoholism.
Vicki E. Buckley,
Associate Director of Administration,
National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health.
Comments
[FR Doc. 2021–14689 Filed 7–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
[OMB Control Number 1615–0046]
Agency Information Collection
Activities; Extension, Without Change,
of a Currently Approved Collection:
Interagency Alien Witness and
Informant Record
U.S. Citizenship and
Immigration Services, Department of
Homeland Security.
ACTION: 30-Day notice.
AGENCY:
The Department of Homeland
Security (DHS), U.S. Citizenship and
Immigration Services (USCIS) will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and clearance in accordance
with the Paperwork Reduction Act of
1995. The purpose of this notice is to
allow an additional 30 days for public
comments.
DATES: Comments are encouraged and
will be accepted until August 11, 2021.
ADDRESSES: Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, must be
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:26 Jul 09, 2021
Jkt 253001
submitted via the Federal eRulemaking
Portal website at https://
www.regulations.gov under e-Docket ID
number USCIS–2006–0062. All
submissions received must include the
OMB Control Number 1615–0046 in the
body of the letter, the agency name and
Docket ID USCIS–2006–0062.
FOR FURTHER INFORMATION CONTACT:
USCIS, Office of Policy and Strategy,
Regulatory Coordination Division,
Samantha Deshommes, Chief,
Telephone number (240) 721–3000
(This is not a toll-free number;
comments are not accepted via
telephone message.). Please note contact
information provided here is solely for
questions regarding this notice. It is not
for individual case status inquiries.
Applicants seeking information about
the status of their individual cases can
check Case Status Online, available at
the USCIS website at https://
www.uscis.gov, or call the USCIS
Contact Center at (800) 375–5283; TTY
(800) 767–1833.
SUPPLEMENTARY INFORMATION:
The information collection notice was
previously published in the Federal
Register on March 16, 2021, at 86 FR
14468, allowing for a 60-day public
comment period. USCIS did not receive
any comments in connection with the
60-day notice.
You may access the information
collection instrument with instructions,
or additional information by visiting the
Federal eRulemaking Portal site at:
https://www.regulations.gov and enter
USCIS–2006–0062 in the search box.
The comments submitted to USCIS via
this method are visible to the Office of
Management and Budget and comply
with the requirements of 5 CFR
1320.12(c). All submissions will be
posted, without change, to the Federal
eRulemaking Portal at https://
www.regulations.gov, and will include
any personal information you provide.
Therefore, submitting this information
makes it public. You may wish to
consider limiting the amount of
personal information that you provide
in any voluntary submission you make
to DHS. DHS may withhold information
provided in comments from public
viewing that it determines may impact
the privacy of an individual or is
offensive. For additional information,
please read the Privacy Act notice that
is available via the link in the footer of
https://www.regulations.gov.
Written comments and suggestions
from the public and affected agencies
should address one or more of the
following four points:
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(2) Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection
Request: Extension, Without Change, of
a Currently Approved Collection.
(2) Title of the Form/Collection:
Interagency Alien Witness and
Informant Record.
(3) Agency form number, if any, and
the applicable component of the DHS
sponsoring the collection: I–854A and I–
854B; USCIS.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: Federal Government.
The Form I–854 will enable the U.S.
Immigration and Customs Enforcement
(ICE) to fulfill those responsibilities. A
law enforcement agency may request S
nonimmigrant classification for an
essential witness or informant by
completing this form, which requires
certifications by both the law
enforcement agency (e.g., that it will
collect the alien’s statutorily-required
quarterly reports and oversee the alien’s
departure, if that becomes necessary)
and the alien. The law enforcement
agency files a properly completed Form
I–854 with the Criminal Division,
Department of Justice, which may
certify the law enforcement agency
request to the U.S. Citizenship and
Immigration Services (USCIS).
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: The estimated total number of
respondents for the information
collection I–854A is 10 and the
estimated hour burden per response is
3 hours. The estimated total number of
respondents for the information
collection I–854B is 30 and the
E:\FR\FM\12JYN1.SGM
12JYN1
]]>Agencies
[Federal Register Volume 86, Number 130 (Monday, July 12, 2021)]
[Notices]
[Pages 36567-36568]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-14689]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice To Announce Request for Information (RFI) Inviting Input
on the ICCFASD 2022-2026 Strategic Plan Outline
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Interagency Coordinating Committee on Fetal Alcohol
Spectrum Disorders (ICCFASD) is developing an updated strategic plan to
guide its efforts over the next five years. As sponsor and chair of the
ICCFASD, the National Institute on Alcohol Abuse and Alcoholism (NIAAA)
will be issuing a Request for Information to seek comments on the draft
outline of the ICCFASD's 2022-2026 Strategic Plan from diverse
stakeholders, including scientific experts, health care providers,
patients and family members, advocacy groups, other federal agencies,
and non-governmental scientific, professional, and healthcare
organizations.
DATES: Comments must be received by August 31, 2021, to ensure
consideration. Responses will be reviewed by ICCFASD members and
considered during the development of the 2022-2026 Strategic Plan.
ADDRESSES: To view and comment on the strategic plan outline, please
visit our online response form: RFI online response form.
FOR FURTHER INFORMATION CONTACT: Tatiana Balachova, ICCFASD Executive
Secretary, National Institute on Alcohol Abuse and Alcoholism, NIH,
6700B Rockledge Drive, Bethesda, MD 20817. Phone: 301-443-5726, Email:
[email protected].
SUPPLEMENTARY INFORMATION: In accordance with the 21st Century Cures
Act, NIH institutes are required to
[[Page 36568]]
regularly update their strategic plans. The Interagency Coordinating
Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) fosters
improved communication, cooperation, and collaboration among
disciplines and federal agencies that address health, education,
developmental disabilities, alcohol research, and social services and
justice issues related to prenatal alcohol exposure. The ICCFASD
envisions that collaborative partnerships, using the resources of the
federal government in partnership with other organizations, will lead
to improved prevention of prenatal alcohol exposure, earlier
identification and improved surveillance of fetal alcohol spectrum
disorders (FASD), and more effective interventions and services for
individuals living with FASD as well as their families. ICCFASD is
sponsored and chaired by the National Institute on Alcohol Abuse and
Alcoholism.
Vicki E. Buckley,
Associate Director of Administration, National Institute on Alcohol
Abuse and Alcoholism, National Institutes of Health.
[FR Doc. 2021-14689 Filed 7-9-21; 8:45 am]
BILLING CODE 4140-01-P
